Article Per Year (5 Year)
p-Index From 2021 - 2026
0.23
P-Index
This Author published in this journals
All Journal Chemistry Indonesian Journal of Chemical Research
Aldillah Herlambang
Chemical Engineering Program, Department of Civil, Chemical and Environmental Engineering, Faculty of Sciences and Technology, Universitas Jambi, Jambi 36361, Indonesia
Biochemistry, Genetics & Molecular Biology Chemistry Engineering Environmental Science

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
Evaluation of 5,5’-Oxybis(1,3,7-Trihydroxy-9H-Xanthen-9-One) as an Anticancer Agent Through In Vitro and In Silico Tests Ayu Nadila Safitri; Aldillah Herlambang; Muhammad Irhash Shalihin; Nurul Pratiwi; Putri Dwi Mulyani; Nania Septiyani; Muktaf Wando Saputra
Indonesian Journal of Chemical Research Vol 14 No 1 (2026): Edition for May 2026
Publisher : Jurusan Kimia, Fakultas Sains dan Teknologi, Universitas Pattimura

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.30598/ijcr.2026.14-saf

Abstract

Breast cancer is among the most common malignancies globally and continues to be a primary cause of cancer-related deaths in women. Modern chemotherapeutic agents often exhibit resistance and lack of selectivity for healthy cells, leading to significant side effects. Consequently, several strategies are essential to overcome resistance and enhance the selectivity and efficacy of chemotherapeutic drugs derived from natural sources. This study investigates the anticancer activity of a new bis-xanthone compound, 5,5'-Oxybis(1,3,7-trihydroxy-9H-xanthen-9-one), in MCF-7 breast cancer cells using a combination of in vitro and in silico approaches. The compound exhibited cytotoxicity against MCF-7 breast cancer cells, with an IC50 value of 30.47 µg/mL. The pharmacokinetic characteristics of bis-xanthone compounds were evaluated using absorption, distribution, metabolism, excretion, and toxicity (ADMET) tests, demonstrating a more favorable profile than that of doxorubicin, a standard anticancer drug.
Co-Authors Ayu Nadila Safitri Muhammad Irhash Shalihin Muktaf Wando Saputra Nania Septiyani Nurul Pratiwi Putri Dwi Mulyani